Peter Dorfmller

List of Publications by Year in Descending Order

58 papers	4,678 citations	33 h-index	61 g-index
61 ext. papers	5,911 ext. citations	10.3 avg, IF	5.05 L-index

#	Paper	IF	Citations
58	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.. *Annals of Cardiothoracic Surgery*, **2022**, 11, 106-119	4.7	3
57	Group 3 Pulmonary Hypertension: From Bench to Bedside.. *Circulation Research*, **2022**, 130, 1404-1422	15.7	1
56	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. *Nature Reviews Cardiology*, **2021**,	14.8	5
55	ERS statement on chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	70
54	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. *Circulation*, **2021**, 144, 52-73	16.7	10
53	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. *Journal of Clinical Immunology*, **2021**, 41, 1549-1562	5.7	2
52	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
51	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.. *European Respiratory Review*, **2021**, 30,	9.8	1
50	Pulmonary capillary haemangiomatosis: a distinct entity?. *European Respiratory Review*, **2020**, 29,	9.8	9
49	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. *Nature Metabolism*, **2020**, 2, 532-546	14.6	4
48	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. *Pulmonary Circulation*, **2020**, 10, 2045894020907884	2.7	1
47	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 148-157	10.2	29
46	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. *American Journal of Respiratory Cell and Molecular Biology*, **2020**, 63, 118-131	5.7	11
45	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. *Circulation*, **2019**, 140, 1409-1425	16.7	41
44	Capillary density in right ventricular myocardium in congenital heart disease. *Journal of Heart and Lung Transplantation*, **2019**, 38, 328-331	5.8	1
43	Pulmonary vascular disease and pulmonary hypertension. *Diagnostic Histopathology*, **2019**, 25, 304-312	0.7	5
42	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. *Chest*, **2019**, 156, 33-44	5.3	14

41	Inhibition of B cell-dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. *JCI Insight*, **2019**, 4,	9.9	9
40	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *European Respiratory Journal*, **2019**, 53,	13.6	407
39	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. *Cardiovascular Research*, **2018**, 114, 880-893	9.9	31
38	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 537-541	10.2	5
37	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. *European Respiratory Journal*, **2018**, 51,	13.6	68
36	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2018**, 37, 647-655	5.8	31
35	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. *Lancet Respiratory Medicine,the*, **2017**, 5, 125-134	35.1	76
34	The importance of capillary density-stroke work mismatch for right ventricular adaptation to chronic pressure overload. *Journal of Thoracic and Cardiovascular Surgery*, **2017**, 154, 2070-2079	1.5	11
33	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033	16.7	75
32	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. *European Heart Journal*, **2017**, 38, 2869-2873	9.5	64
31	The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. *Annals of the American Thoracic Society*, **2016**, 13 Suppl 3, S215-21	4.7	83
30	Resident PW1+ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. *Circulation Research*, **2016**, 118, 822-33	15.7	28
29	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. *Circulation*, **2016**, 133, 1371-85	16.7	98
28	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". *Circulation*, **2016**, 133, e592-3	16.7	4
27	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1668-1681	13.6	49
26	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2016**, 47, 1518-34	13.6	134
25	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 1273-1285	10.2	61
24	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. *Circulation*, **2016**, 133, 1747-60	16.7	61

23	Endothelial-to-mesenchymal transition in pulmonary hypertension. *Circulation*, **2015**, 131, 1006-18	16.7	320
22	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. *Circulation*, **2015**, 132, 834-47	16.7	80
21	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 983-97	10.2	108
20	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. *European Respiratory Journal*, **2015**, 46, 1721-31	13.6	55
19	Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet. *Journal of Visualized Experiments*, **2015**, e53133	1.6	6
18	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. *American Journal of Pathology*, **2015**, 185, 356-71	5.8	116
17	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nature Genetics*, **2014**, 46, 65-9	36.3	259
16	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. *Circulation*, **2014**, 129, 1332-40	16.7	110
15	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. *Circulation*, **2014**, 129, 1586-97	16.7	131
14	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. *European Respiratory Journal*, **2014**, 44, 1069-72	13.6	33
13	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. *European Respiratory Journal*, **2014**, 44, 1275-88	13.6	135
12	Right ventricular plasticity in a porcine model of chronic pressure overload. *Journal of Heart and Lung Transplantation*, **2014**, 33, 194-202	5.8	15
11	Relevant issues in the pathology and pathobiology of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D4-12	15.1	379
10	Pulmonary arterial hypertension. *Orphanet Journal of Rare Diseases*, **2013**, 8, 97	4.2	168
9	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 189-96	10.2	42
8	Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. *Circulation*, **2013**, 128, 512-23	16.7	85
7	Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 311-21	10.2	194
6	Inflammation in Pulmonary Arterial Hypertension **2012**, 213-229		1

5	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. *Respiratory Research*, **2011**, 12, 119	7.3	64
4	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. *Journal of Clinical Investigation*, **2011**, 121, 2888-97	15.9	70
3	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 81-8	10.2	336
2	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. *Medicine (United States)*, **2008**, 87, 220-233	1.8	229
1	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. *Human Pathology*, **2007**, 38, 893-902	3.7	238